Conformis, Inc. (NASDAQ:CFMS) announced today financial results for
the fourth quarter and year ended December 31, 2020.
Fourth Quarter 2020 Summary
- Total revenue of $16.7 million, a decrease of 16%
year-over-year on a reported basis and 17% on a constant currency
basis.
- Product revenue of $16.5 million, a decrease of 16%
year-over-year on a reported basis and 17% on a constant currency
basis. Product revenue increased 3% over the third quarter of
2020. - U.S. product revenue of $14.4 million, a decrease of
16% year-over-year. - Rest-of-world product revenue of $2.1
million, a decrease of 16% year-over-year on a reported basis and
22% on a constant currency basis.
- Royalty and licensing revenue of $0.2 million, an increase of
4% year-over-year.
- Gross margin of 47%, a decrease of 180 basis points
year-over-year.
- Total operating expenses remained flat year-over-year.
Year End 2020 Summary
- Total revenue of $68.8 million, a decrease of 11%
year-over-year on a reported and constant currency basis.
- Product revenue of $58.5 million, a decrease of 24%
year-over-year on a reported and constant currency basis. -
U.S. product revenue of $50.7 million, a decrease of 24%
year-over-year - Rest-of-world product revenue of $7.8
million, a decrease of 18% year-over-year on a reported basis and
19% on a constant currency basis.
- Royalty and licensing revenue of $10.2 million, an increase of
1,210% year-over-year, as a result of our $9.6 million settlement
and license agreement with Zimmer Biomet in the second quarter of
2020.
- Gross margin of 49%, an increase of 160 basis points
year-over-year, was driven primarily by the increase in royalty and
licensing revenue in 2020.
- Total operating expenses decreased 5% year-over-year.
2021 Expected Product Launch
Highlights
- Cordera™ Match Hip Launch
Rollout
- Stryker Patient-Specific Guides
Launch
- New standard knee offering
launch
"Though the COVID-19 pandemic continues to create uncertainty in
orthopedic procedure levels, Conformis has remained committed to
the continuation of our new product development schedule. As such,
we expect 2021 to be an exciting year in regards to new product
offerings, especially our new total knee system. While this system
can be used in the in-patient and out-patient settings, we are
particularly focused on the ambulatory care setting,” said Mark
Augusti, President and Chief Executive Officer. “Our recently
completed $85 million capital raise gives us the flexibility to
drive our growth strategy.”
|
Three Months EndedDecember
31, |
Increase/(decrease) |
($, in thousands) |
2020 |
2019 |
$ Change |
% Change |
% Change |
|
|
|
|
(as reported) |
(constant currency) |
United States |
$ |
14,439 |
|
$ |
17,225 |
|
$ |
(2,786 |
) |
|
(16 |
) |
% |
(16 |
) |
% |
Rest of world |
|
2,093 |
|
|
2,506 |
|
|
(413 |
) |
|
(16 |
) |
% |
(22 |
) |
% |
Product
revenue |
|
16,532 |
|
|
19,731 |
|
|
(3,199 |
) |
|
(16 |
) |
% |
(17 |
) |
% |
Royalty and licensing
revenue |
|
165 |
|
|
158 |
|
|
7 |
|
|
4 |
|
% |
4 |
|
% |
Total
revenue |
$ |
16,697 |
|
$ |
19,889 |
|
$ |
(3,192 |
) |
|
(16 |
) |
% |
(17 |
) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter 2020 Financial Results
Total revenue for the three-month period ended December 31,
2020 decreased $3.2 million to $16.7 million, or 16% year-over-year
on a reported basis and 17% on a constant currency basis. Total
revenue in each of the fourth quarter of 2020 and 2019 includes
royalty and licensing revenue of $0.2 million, related to patent
license agreements.
Product revenue decreased $3.2 million to $16.5 million, or 16%
year-over-year on a reported basis and 17% on a constant currency
basis. U.S. product revenue decreased $2.8 million to $14.4
million, or 16% year-over-year, and rest-of-world product revenue
decreased $0.4 million to $2.1 million, or 16% year-over-year on a
reported basis and 22% on a constant currency basis. Conformis Hip
System sales for the fourth quarter of 2020, which were all in the
United States, were up 5% to $0.6 million.
Total gross profit decreased $1.9 million to $7.8 million, or
47% of revenue, in the fourth quarter of 2020, compared to $9.7
million, or 49% of revenue, in the fourth quarter of 2019. The 180
basis point decrease in gross margin year-over-year was driven
primarily by lower volume and cancelled case inventory expense.
Total operating expenses remained flat year-over-year.
Net loss was $6.6 million, or $0.08 per basic share, in the
fourth quarter of 2020, compared to a net loss of $5.4 million, or
$0.08 per basic share, for the same period last year. Net loss in
the fourth quarter of 2020 included foreign currency exchange
income of $1.7 million compared to foreign currency exchange income
of $0.9 million in the same period last year. Net loss per basic
share calculations assume weighted average basic shares outstanding
of 80.0 million for the fourth quarter of 2020, compared to 65.5
million for the same period last year.
|
Twelve Months Ended December 31, |
Increase/(decrease) |
($, in thousands) |
2020 |
|
2019 |
$ Change |
% Change |
% Change |
|
|
|
|
|
|
|
|
(as reported) |
(constant currency) |
United States |
$ |
50,736 |
|
$ |
67,151 |
|
$ |
(16,415 |
) |
|
(24 |
) |
% |
(24 |
) |
% |
Rest of world |
7,804 |
|
9,498 |
|
(1,694 |
) |
|
(18 |
) |
% |
(19 |
) |
% |
Product
revenue |
58,540 |
|
76,649 |
|
(18,109 |
) |
|
(24 |
) |
% |
(24 |
) |
% |
Royalty and licensing
revenue |
10,221 |
|
780 |
|
9,441 |
|
|
1,210 |
|
% |
1,210 |
|
% |
Total
revenue |
$ |
68,761 |
|
$ |
77,429 |
|
$ |
(8,668 |
) |
|
(11 |
) |
% |
(11 |
) |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year 2020 Financial Results
Total revenue for the year ended December 31, 2020
decreased $8.7 million to $68.8 million, or 11% year-over-year on a
reported and constant currency basis. Total revenue includes
royalty and licensing revenue of $10.2 million for the year ended
2020 and $0.8 million for the year ended 2019 related to patent
license agreements. The increase in royalty and licensing revenue
was driven by $9.6 million in revenue recognized in the second
quarter under the settlement and license agreement with Zimmer
Biomet.
Product revenue decreased $18.1 million to $58.5 million, or 24%
year-over-year on a reported and constant currency basis. U.S.
product revenue decreased $16.4 million to $50.7 million, or 24%
year-over-year, and rest-of-world product revenue decreased $1.7
million to $7.8 million, or 18% year-over-year on a reported basis
and 19% on a constant currency basis. Conformis Hip System sales
for 2020, which were all in the United States, were up 26.1% to
$2.5 million.
Total gross profit decreased $3.0 million to $33.7 million, or
49% of revenue, in 2020, compared to $36.7 million, or 47% of
revenue, in 2019. The 160 basis point increase in gross margin
year-over-year was primarily driven by the $9.6 million licensing
revenue recognized as a result of the settlement and license
agreement with Zimmer Biomet, offset by lower volume and cancelled
case inventory expense during the year.
Total operating expenses decreased $3.0 million to $58.8
million, or 5% year-over-year. The decrease in expenses was
primarily driven by lower variable expenses as a result of the
decline in revenue as well as lower travel and marketing-related
expenses.
Net loss was $24.3 million, or $0.34 per basic share for 2020,
compared to a net loss of $28.5 million, or $0.44 per basic share,
for 2019. Net loss included foreign currency exchange income of
$3.2 million in 2020, compared to foreign currency exchange loss of
$0.7 million in 2019. Net loss per basic share calculations assume
weighted average basic shares outstanding of 71.7 million for 2020,
compared to 64.1 million for 2019.
As of December 31, 2020, cash and cash equivalents totaled
$28.7 million, compared to $26.4 million as of December 31,
2019.
Outlook
Historically, we see a drop in first quarter revenue compared to
the preceding fourth quarter as many health plans reset on January
1. In addition, we have continued to experience pressure on our
business from reduced elective procedures into 2021. Accordingly,
we expect our first quarter product revenue to be in the range of
$13.0 million to $14.0 million. We believe this pressure will
continue through the second quarter, but that we may see elective
volumes improve in the third quarter as vaccines become more widely
available.
Note on Non-GAAP Financial
Measures
In addition to disclosing financial measures prepared in
accordance with U.S. generally accepted accounting principles
(GAAP), the Company provides certain information regarding the
Company's financial results or projected financial results on a
non-GAAP "constant currency basis." This information estimates the
impact of changes in foreign currency rates on the translation of
the Company's current or projected future period financial results
as compared to the applicable comparable period. This impact is
derived by taking the adjusted current or projected local currency
results and translating them into U.S. dollars based upon the
foreign currency exchange rates for the applicable comparable
period. It does not include any other effect of changes in foreign
currency rates on the Company's results or business. Non-GAAP
information is not a substitute for, and is not superior to,
information presented on a GAAP basis. Company management uses
these non-GAAP measures internally to measure operational
performance.
Webcast
As previously announced, Conformis will conduct a webcast today
at 4:30 PM Eastern Time. Management will discuss financial results
and strategic matters. The webcast will be live at
https://edge.media-server.com/mmc/p/z2dhee2u.
The archive of the webcast will be available on the Company's
website for 30 days.
About Conformis, Inc.
Conformis is a medical technology company that uses its
proprietary iFit® Image-to-Implant® technology platform to develop,
manufacture, and sell joint replacement implants and instruments
that are individually sized and shaped, which we refer to as
personalized, individualized, or sometimes as customized, to fit
each patient's unique anatomy. Conformis offers a broad line of
sterile, personalized knee and hip implants and single-use
instruments delivered to hospitals and ambulatory surgical centers.
In clinical studies, the Conformis iTotal CR knee replacement
system demonstrated superior clinical outcomes, including better
function and greater patient satisfaction, compared to traditional,
off-the-shelf implants. Conformis owns or exclusively in-licenses
issued patents and pending patent applications that cover
personalized implants and patient-specific instrumentation for all
major joints.
For more information, visit www.conformis.com. To receive future
releases in e-mail alerts, sign up at http://ir.conformis.com/.
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this press release about our future expectations,
plans and prospects, including statements about the impact of the
novel coronavirus (COVID-19) pandemic and the actions we are taking
and planning in response, our planned launch of a new program aimed
at developing a knee replacement offering targeted at hospital
outpatient and ambulatory surgery centers, the anticipated timing
of our product launches, whether or when restrictions on elective
surgeries will be relaxed and demand for procedures will increase,
and our financial position and results, total revenue, product
revenue, gross margin, operations and growth, as well as other
statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may,"
"might," "plan," "potential," "predict," "project," "should,"
"target," "will," or "would" or the negative of these terms or
other and similar expressions are intended to identify
forward-looking statements within the meaning of the safe harbor
provisions of The Private Securities Litigation Reform Act of 1995,
although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make as a result of a variety of
risks and uncertainties, including risks related to the novel
coronavirus pandemic and the response to the pandemic; whether our
cash resources will be sufficient to fund our continuing operations
for the periods anticipated; risks related to our estimates and
expectations regarding our revenue, gross margin, expenses, revenue
growth and other results of operations, and the other risks and
uncertainties described in the "Risk Factors" sections of our
public filings with the U.S. Securities and Exchange Commission. In
addition, the forward-looking statements included in this press
release represent our views as of the date hereof. We anticipate
that subsequent events and developments may cause our views to
change. However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date hereof.
CONFORMIS, INC. AND SUBSIDIARIES |
Consolidated Statements of Operations |
|
(in thousands, except share and per share
data) |
|
|
|
|
|
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
|
2020 |
2019 |
|
2020 |
2019 |
|
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
$ |
16,532 |
|
|
$ |
19,731 |
|
|
|
$ |
58,540 |
|
|
$ |
76,649 |
|
|
Royalty and licensing |
|
165 |
|
|
|
158 |
|
|
|
|
10,221 |
|
|
|
780 |
|
|
Total revenue |
|
16,697 |
|
|
|
19,889 |
|
|
|
|
68,761 |
|
|
|
77,429 |
|
|
Cost of revenue |
|
8,898 |
|
|
|
10,233 |
|
|
|
|
35,046 |
|
|
|
40,692 |
|
|
Gross profit |
|
7,799 |
|
|
|
9,656 |
|
|
|
|
33,715 |
|
|
|
36,737 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing |
|
6,226 |
|
|
|
7,283 |
|
|
|
|
22,646 |
|
|
|
28,514 |
|
|
Research and development |
|
3,345 |
|
|
|
3,055 |
|
|
|
|
11,939 |
|
|
|
12,457 |
|
|
General and administrative |
|
5,900 |
|
|
|
5,112 |
|
|
|
|
24,244 |
|
|
|
20,895 |
|
|
Total operating expenses |
|
15,471 |
|
|
|
15,450 |
|
|
|
|
58,829 |
|
|
|
61,866 |
|
|
Loss from operations |
|
(7,672 |
) |
|
|
(5,794 |
) |
|
|
|
(25,114 |
) |
|
|
(25,129 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
10 |
|
|
|
74 |
|
|
|
|
76 |
|
|
|
330 |
|
|
Interest expense |
|
(604 |
) |
|
|
(579 |
) |
|
|
|
(2,373 |
) |
|
|
(2,942 |
) |
|
Foreign currency exchange transaction income (loss) |
|
1,669 |
|
|
|
876 |
|
|
|
|
3,160 |
|
|
|
(692 |
) |
|
Total other income (expenses) |
|
1,075 |
|
|
|
371 |
|
|
|
|
863 |
|
|
|
(3,304 |
) |
|
Loss before income taxes |
|
(6,597 |
) |
|
|
(5,423 |
) |
|
|
|
(24,251 |
) |
|
|
(28,433 |
) |
|
Income tax provision |
|
25 |
|
|
|
10 |
|
|
|
|
42 |
|
|
|
45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
$ |
(6,622 |
) |
|
$ |
(5,433 |
) |
|
|
$ |
(24,293 |
) |
|
$ |
(28,478 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.08 |
) |
|
$ |
(0.08 |
) |
|
|
$ |
(0.34 |
) |
|
$ |
(0.44 |
) |
|
Weighted average common shares
outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
79,972,586 |
|
|
|
65,520,222 |
|
|
|
|
71,699,615 |
|
|
|
64,122,455 |
|
|
CONFORMIS, INC. AND SUBSIDIARIES |
Consolidated Balance Sheets |
(in thousands, except share and per share
data) |
|
|
|
|
|
December 31, 2020 |
|
December 31, 2019 |
Assets |
(unaudited) |
|
|
Current Assets |
|
|
|
Cash and cash equivalents |
$ |
28,673 |
|
|
$ |
26,394 |
|
Accounts receivable, net |
8,515 |
|
|
11,066 |
|
Royalty and licensing receivable |
1,256 |
|
|
165 |
|
Inventories |
12,585 |
|
|
12,074 |
|
Prepaid expenses and other current assets |
2,315 |
|
|
2,815 |
|
Total current assets |
53,344 |
|
|
52,514 |
|
Property and equipment, net |
12,240 |
|
|
13,356 |
|
Operating lease right-of-use assets |
5,215 |
|
|
5,853 |
|
Other Assets |
|
|
|
Restricted cash |
462 |
|
|
462 |
|
Other long-term assets |
239 |
|
|
211 |
|
Total assets |
$ |
71,500 |
|
|
$ |
72,396 |
|
|
|
|
|
Liabilities and stockholder's
equity |
|
|
|
Current liabilities |
|
|
|
Accounts payable |
$ |
4,918 |
|
|
$ |
6,920 |
|
Accrued expenses |
7,213 |
|
|
7,135 |
|
Operating lease liabilities |
1,620 |
|
|
1,469 |
|
Advance on research and development |
3,168 |
|
|
2,331 |
|
Contract liability |
14,000 |
|
|
— |
|
Total current liabilities |
30,919 |
|
|
17,855 |
|
Other long-term liabilities |
— |
|
|
1,500 |
|
Contract liability |
— |
|
|
12,000 |
|
Long-term debt, less debt issuance costs |
25,003 |
|
|
19,623 |
|
Operating lease liabilities |
4,206 |
|
|
5,071 |
|
Total liabilities |
60,128 |
|
|
56,049 |
|
Commitments and
contingencies |
|
|
|
|
|
Stockholders' equity |
|
|
|
Preferred stock, $0.00001 par value: |
|
|
|
Authorized: 5,000,000 shares authorized at December 31, 2020 and
December 31, 2019; no shares issued and outstanding as of
December 31, 2020 and December 31, 2019 |
— |
|
|
— |
|
Common stock, $0.00001 par value: |
|
|
|
Authorized: 200,000,000 shares authorized at December 31, 2020 and
December 31, 2019; 95,546,577 and 70,427,400 shares issued and
outstanding at December 31, 2020 and December 31, 2019,
respectively |
1 |
|
|
1 |
|
Additional paid-in
capital |
543,809 |
|
|
521,356 |
|
Accumulated deficit |
(528,438 |
) |
|
(504,145 |
) |
Accumulated other
comprehensive loss |
(4,000 |
) |
|
(865 |
) |
Total stockholders' equity |
11,372 |
|
|
16,347 |
|
Total liabilities and stockholders' equity |
$ |
71,500 |
|
|
$ |
72,396 |
|
|
|
|
|
|
|
|
|
CONTACT:
Investor Relations
ir@conformis.com
(781) 374-5598
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Conformis (NASDAQ:CFMS)
Historical Stock Chart
From Apr 2023 to Apr 2024